Please login to the form below

Not currently logged in

ZPB Associates appoints David Rowley as a Board adviser

Rowley was the founder and CEO of Huntsworth Health and co-founder and CEO of Open Health

David Rowley

Healthcare communications agency ZPB Associates has announced the appointment of David Rowley to the position of Board adviser.

Rowley joins ZPB as a health agency veteran and entrepreneur, having held a long-standing record of creating successful healthcare communications agencies. To date, he has served as founder and CEO of Huntsworth Health and also served as co-founder and CEO of Open Health.

Sharing his thoughts on his new position at the agency, Rowley said: “ZPB have a unique and very relevant profile in the dynamic access and communications space, and coupled with a very able leadership team will continue to grow from strength to strength. I’m delighted to get involved and support Zoe, the Exec Team and the Board in realising its potential”

With extensive experience in healthcare market access and strategy, in his new role, Rowley will support the growth of the business by driving its reach into the pharmaceutical sector through its expanded market access and insight offering.

Zoe Bedford, CEO of ZPB Associates said: “We are incredibly proud to have doubled the size of our business in the past 18 months, delivering outstanding work and award-winning campaigns. This growth and success underlines ZPB’s unique offer to our pharma, digital health and services clients. Appointing David to our Board will accelerate this growth, marking the next stage in our ambitious growth strategy.

Article by
Fleur Jeffries

11th May 2022

From: Marketing


COVID-19 Updates and Daily News

Featured jobs


Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...